Clinical trial NCT06071143: Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease
Official title: A Single Arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Chronic Kidney Diseases
Keywords: CKD
Urine-derived Stem cell
stem cell
EHLBIO
UDSC
Lead sponsor: EHL Bio Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-10-06
Enrollment: 6
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients with Chronic Kidney Disease.

The aim of this study is to evaluate the safety and preliminary efficacy of KDSTEM Inj. in the treatment in Patients with Chronic Kidney Disease.

Detailed description: This clinical trial is a single-arm, open-labelled, dose-escalation, single-center Phase 1 study. Its aim is to evaluate the safety, tolerability, and preliminary efficacy of autologous urine-derived stem cells in patients with Chronic Kidney Disease.

If subjects voluntarily sign a written agreement to participate in this clinical trial, the subjects shall undergo the necessary examinations, as outlined in the clinical trial protocol, approximately one month prior to the administration of the investigational product.

After assessing the suitability of the subjects and ensuring participants meet the inclusion/exclusion criteria, eligible subjects will be assigned to different treatment arms. Subjects determined eligible by the investigator for receiving the investigational product on the scheduled administration day will receive a intravenous dose of the investigational product in visit 2, visit 3, and visit 4.

Safety and Efficacy assessments are conducted at 4, 8, 12, 16, 20, and 24 weeks after from the first administration to last administration of the investigational product, spanning a total of 24 weeks.

After all the subjects have completed visit 10, Safety and Efficacy will be analyzed.

Eligibility criteria: Inclusion Criteria:

1. Male or female aged between 19 and 80 at the time of signing the agreement
2. Chronic kidney disease patients with an eGFR of 20 to 59 ml/min/1.73m² by MDRD at the screening and baseline
3. Male or female of childbearing age agreed to use accurate birth control method during this clinical trial
4. Subjects voluntarily signed an agreement in writing for this clinical trial

Exclusion Criteria:

1. Subjects who meet any of the following conditions at the screening visit

   1. Systemic infection
   2. HIV, HBV, HCV, Syphilis (+)
   3. Blood pressure higher than 190mmHg of SBP or 110mmHg of DBP
   4. AST or ALT higher than 3 times the upper limit of normal values
2. Subjects who received hemodialysis within 12 weeks prior to the screening or will be receive hemodialysis during this clinical trial
3. Subjects who received kidney transplantation or will be receive kidney transplantation during this clinical trial
4. Subjects diagnosed with the following diseases

   1. Solid Tumors or Hematologic Malignancies within 5 years prior to the screening
   2. Cognitive disorder, Alzheimer's disease or mental illness be clinically significant.
   3. Alcohol or drug abuse
   4. Severe Respiratory disease (Chronic Obstructive Pulmonary Disease, asthma, pneumonia, pulmonary embolism and pneumothorax, etc.)
   5. Stroke
   6. Heart related diseases (within 3 months prior to the screening severe cardiovascular conditions (angina Pectoris, myocardial infarction, unstable arrhythmia, heart failure, etc.)
5. Subjects who received cell therapy or another clinical trial product/device within 4 weeks prior to the screening
6. Subjects who were hypersensitivity reaction pertaining to penicillin, streptomycin, and amphotericin B
7. Subjects, as determined by an investigator, receiving treatment anticipated to affect the results of the clinical trials
8. Subjects being pregnant, providing breast milk, resulted in positive pregnancy test at screening or planning for pregnancy during this clinical trial
9. etc. Subjects determined unsuitable for this clinical trial by the investigator

Primary outcomes:
measure: The number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0
timeFrame: 28 weeks follow-up after first injection
Secondary outcomes:
measure: eGFR
timeFrame: From the first injection until 28 weeks later
measure: BUN
timeFrame: From the first injection until 28 weeks later
measure: Serum creatinine
timeFrame: From the first injection until 28 weeks later
measure: UPCR
timeFrame: From the first injection until 28 weeks later
measure: UACR
timeFrame: From the first injection until 28 weeks later
measure: NGAL(Neutrophil Gelatinase Associated Lipocalin)
timeFrame: The first administration time, 4 weeks and 24 weeks after the third administration.
measure: IL-6, IL-8, CCL18, TNF-α, α-Klotho
timeFrame: The first administration time, 4 weeks and 24 weeks after the third administration.
Other outcomes:
Locations:
city: Daejeon
country: Korea, Republic of
facility: Chungnam National University Hospital
state: Chungcheongnam-do
Study officials:
affiliation: Chungnam National University Hospital
name: Dae-Eun Choi, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: